Based on previous pre-clinic studies, the miRNAs validated by RT-qPCR in our study are involved in alteration of glucose and lipid metabolism via insulin pathways (let-7f-5p, miR-10a-5p, miR-322)20–22, in cardiomyocytes apoptosis (miR-19b-3p, miR-25-3p, miR-30e-5p, miR-140-5p, miR-199a-3p, miR-499)23–28, in mitochondrial function (miR-181a/b)29, in pro-inflammatory signalling (miR-146a-5p, miR-155, miR-181b-3p, miR-3473b)30–33, and in cardiac hypertrophy (miR-451)34 and myocardial fibrosis process (miR-19b)35,36. The gene discussed is INS; the disease is cardiac hypertrophy.